

Table 1

Synthesis of Benzimidazoles **7**

Nb	R	M.p., °C (Solvent)	Reaction Time (Minutes)		Yield, [a] %	Formula	Analysis, % Calcd./Found		
			165°	220°			C	H	N
7a	H	> 260 C ₂ H ₅ OH	20	60	93	C ₁₁ H ₁₁ N ₃ O	65.66 65.27	5.51 5.72	20.88 20.96
7b	CH ₃	> 260 C ₂ H ₅ OH/H ₂ O	120	25	57	C ₁₂ H ₁₃ N ₃ O	66.96 66.59	6.09 5.85	19.52 19.86
7c	CH ₂ -Ph	239 C ₂ H ₅ OH	45	15	65	C ₁₈ H ₁₇ N ₃ O	74.21 74.02	5.88 6.17	14.42 14.52
7d	CH ₂ -Ph- <i>p</i> -Cl	215 C ₂ H ₅ OH/H ₂ O	150	40	58	C ₁₈ H ₁₆ N ₃ OCl	66.36[b] 65.80	4.95 4.98	12.90 12.58
7e	CH ₂ -Ph- <i>o</i> -CH ₃	263 C ₂ H ₅ OH/H ₂ O	120	20	64	C ₁₉ H ₁₉ N ₃ O	74.73 74.53	6.27 6.34	13.76 13.58
7f	CH ₂ -C ₄ H ₃ S	190 CH ₃ CN	30	10	45	C ₁₆ H ₁₅ N ₃ OS	64.62 64.54	5.08 5.06	14.13 14.23
7g	CH ₂ -C ₃ HNS-Ph	233 CH ₃ OH/H ₂ O	150	15	53	C ₂₁ H ₁₈ N ₄ OS	67.36 67.29	4.85 4.80	14.96 15.02

[a] Crude Yield; [b] we did not succeed in obtaining a better analysis.

Table 2

Spectral Properties of Benzimidazoles **7**

Nb	R	IR (nujol) cm ⁻¹	¹ H NMR (Solvent) ppm
7a	H	1595 (C=C arom.); 1690 (C=O); 3180-3400 (N-H)	(DMSO d ₆): 2.0-2.6 (m, 4H); 4.7-5.0 (m, 1H), 7.0-7.7 (m, 4H); 8.10 (s, 1H); 8.40 (s, 1H)
7b	CH ₃	1590 (C=C arom.); 1690 (C=O)	(DMSO d ₆): 2.0-2.9 (m, 4H); 2.65 (s, 3H); 4.7-5.2 (m, 1H); 7.0-7.6 (m, 4H); 8.50 (s, 1H)
7c	CH ₂ -Ph	1590 (C=C arom.); 1690 (C=O)	(CDCl ₃): 2.0-2.9 (m, 4H); 3.70 (d, J = 14.9 Hz, 1H); 4.8-5.1 (m, 1H); 5.05 (d, J = 14.9 Hz, 1H); 6.9-7.8 (m, 9H); 9.9 (s, 1H)
7d	CH ₂ -Ph- <i>p</i> -Cl	1595 (C=C arom.); 1695 (C=O)	(CDCl ₃): 2.1-2.9 (m, 4H); 3.67 (d, J = 14.4 Hz, 1H); 5.06 (d, J = 14.4 Hz, 1H); 4.8-5.15 (m, 1H), 7.1-8.0 (m, 9H)
7e	CH ₂ -Ph- <i>o</i> -CH ₃	1595-1600 (C=C arom.); 1690 (C=O)	(CDCl ₃): 2.21 (s, 3H); 2.3-2.9 (m, 4H); 3.9 (d, J = 14.8 Hz, 1H); 4.9-5.2 (m, 1H); 5.1 (d, J = 14.8 Hz, 1H); 6.9-7.9 (m, 9H)
7f	CH ₂ -C ₄ H ₃ S	1590 1605 (C=C arom.); 1690 (C=O)	(CDCl ₃): 2.0-2.8 (m, 4H); 4.01 (d, J = 15.0 Hz, 1H); 5.15 (d, J = 15.0 Hz, 1H); 4.8-5.2 (m, 1H); 6.85 (s, 1H); 6.92 (s, 1H); 7.1-7.5 (m, 4H); 7.5-7.9 (m, 2H)
7g	CH ₂ -C ₃ HNS-Ph	1595-1610 (C=C arom.); 1700 (C=O)	(CDCl ₃): 2.1-2.7 (m, 4H); 4.31 (d, J = 15.0 Hz, 1H); 4.81 (d, J = 15.0 Hz, 1H); 5.0-5.3 (m, 1H); 7.1-7.4 (m, 4H); 7.8-8.1 (m, 2H)

Table 3

Physical Properties of New Pyroglutamic Hydrazides **12** and Diacylhydrazines **10**


Nb	R ₁	R ₂	M.p., °C	Yield, %	Formula	Analysis, % Calcd./Found		
						C	H	N
12c	CH ₂ -Ph- <i>o</i> -Cl		[a]	96[b]	C ₁₂ H ₁₄ N ₃ O ₂ Cl	[a]	[a]	[a]
12d	CH ₂ -Ph- <i>p</i> -CH ₃		152	98[b]	C ₁₃ H ₁₇ N ₃ O ₂	63.12 63.37	6.93 7.03	16.99 16.74
10a	CH ₃	CH ₃	172	89[b]	C ₈ H ₁₃ N ₃ O ₃	48.22 48.06	6.58 6.69	21.10 21.09
10c	CH ₂ -Ph	CH ₂ -O-Ph- <i>p</i> -Cl	175	75[b]	C ₂₀ H ₂₀ N ₃ O ₄ Cl	59.83 59.88	5.03 5.07	10.47 10.31
10d	CH ₂ -Ph	Ph-3,4,5-(OCH ₃) ₃	160	46	C ₂₂ H ₂₅ N ₃ O ₆	61.82 61.51	5.90 5.97	9.83 10.14
10e	CH ₂ -Ph	Ph- <i>p</i> -Cl	144	67	C ₁₉ H ₁₈ N ₃ O ₃ Cl.H ₂ O	58.54 58.22	5.17 5.14	10.78 10.60
10f	CH ₂ -Ph- <i>o</i> -Cl	CF ₃	208	72[b]	C ₁₄ H ₁₃ N ₃ O ₃ F ₃ Cl	46.23 46.19	3.60 3.55	11.55 11.46
10g	CH ₂ -Ph- <i>p</i> -CH ₃	CH ₂ -C ₄ H ₃ S	210	77[b]	C ₁₉ H ₂₁ N ₃ O ₃ S	61.44 61.44	5.70 5.78	11.31 11.27

[a] Hygroscopic, not purified before next step; [b] Crude yield.

B - Oxadiazole **8**.


To date, the main reaction used for the synthesis of 1,3,4-oxadiazoles is the dehydration of diacylhydrazines, performed either thermally [12], or with the aid of an acidic dehydrating agent, such as sulfuric acid [13], acetic anhydride [14], phosphorus oxychloride [15], polyphosphoric acid (PPA) [16], or polyphosphate ester (PPE) [17]. In the pyroglutamic acid series, we have previously shown [18] that the best dehydrating agent for the synthesis of oxadiazole **8b** is the mixture methanesulfonic acid/phosphoric anhydride (Scheme 2).

Scheme 2




In this work, we chose to use the heterocyclization induced by silyl groups, recently developed in our laboratory (Scheme 3) [19], because these reactions can accommodate acid sensitive compounds, and because an aqueous treatment is not required; this method generally gives very good yields in the synthesis of oxadiazoles, and can be realized by using very different catalysts such as triflic acid, iron trichloride, fluoride ion, palladium over carbon, or azaisobutyronitrile [20].

Scheme 3




Scheme 4



The starting materials, diacylhydrazines **10a-g** were prepared by reaction of the pyroglutamic hydrazides **12a-e** with acetic anhydride, or acyl chlorides, as already reported for diacylhydrazine **10b** [18]. The hydrazides **12a-d** were obtained from the action of hydrazine monohydrate on pyroglutamic esters **11a-d** (Scheme 4) [21] as previously described for the preparation of hydrazides **12a-b** [21a-b]. Interestingly, the reaction of hydrazine monohydrate with acetate **12a** [22] at 0° only afforded methyl *N*-hydroxymethylpyroglutamate **13** [22] and acetic hydrazide (Scheme 5).

Scheme 5



Physical properties of the new compounds **10** and **12** are reported in Tables 3 and 4; some hydrazides **10** are highly hygroscopic and have been acylated without complete purification.

Scheme 6 shows the synthesis of oxadiazoles **8**. The cyclization was performed one-pot by refluxing the diacylhydrazines **10** in hexamethyldisilazane (HMDS), in the presence of tetrabutylammonium fluoride or trifluoromethanesulfonic acid. In cases where formation of the intermediate


Table 4

Spectral Properties of New Pyroglutamic Hydrazides **12** and Diacylhydrazines **10**

Nb	R ₁	R ₂	IR (nujol) cm ⁻¹	¹ H NMR (Solvent) ppm
12c	CH ₂ -Ph- <i>o</i> -Cl		1655-1685 (C=O); 3290 (N-H)	(CDCl ₃): 1.29 (s, 2H) [a]; 1.9-2.95 (m, 4H); 2.3-1.8 (m, 1H) [a]; 3.75-4.15 (m, 1H); 4.23 (d, J = 14.9 Hz, 1H); 4.96 (d, J = 14.9 Hz, 1H); 7.26 (s, 4H)
12d	CH ₂ -Ph- <i>p</i> -CH ₃		1655-1685 (C=O); 3260-3300 (N-H)	(CDCl ₃): 1.7-2.8 (m, 4H); 2.29 (s, 3H); 3.78 (d, J=14.4Hz, 1H); 3.95 (m, 1H); 3.1-5.3 (m, 2H); 4.96 (d, J = 14.4 Hz, 1H); 6.9-7.3 (m, 1H) [a]; 7.07 (s, 4H)
10a	CH ₃	CH ₃	1655-1700-1710 (C=O); 3200 (N-H)	(CDCl ₃ /DMSOd ₆ ; 70/30): 1.55-2.45 (m, 4H); 1.95 (s, 3H); 2.74 (s, 3H); 4.0-4.35 (m, 1H)
10c	CH ₂ -Ph	CH ₂ -O-Ph- <i>p</i> -Cl	1490-1510 (C=C arom.); 1690 (C=O); 3050-3175 (N-H)	(CDCl ₃): 2.0-2.6 (m, 4H); 3.8-4.15 (m, 1H); 3.91 (d, J = 14.8 Hz, 1H); 4.50 (s, 2H); 5.09 (d, J = 14.8 Hz, 1H); 6.86 (d, J = 9.0 Hz, 2H); 7.22 (s, 5H); 7.26 (d, J = 9.0 Hz, 2H); 8.2-9.7 (m, 2H) [a]
10d	CH ₂ -Ph	Ph-3,4,5-(OCH ₃) ₃	1140 (C-O); 1600- 1540-1515 (C=C arom.); 1715-1675 (C=O); 3260 (N-H)	(CDCl ₃): 2.0-2.7 (m, 4H); 3.83 (s, 3H); 3.91 (s, 6H); 3.7-4.1 (m, 1H); 3.91 (d, J = 15.0 Hz, 1H); 5.08 (d, J = 15.0 Hz, 1H); 7.25-7.50 (m, 7H)
10e	CH ₂ -Ph	Ph- <i>p</i> -Cl	1485-1510 (C=C arom.); 1625-1655- 1690-1710 (C=O); 3215-3420 (N-H)	(CDCl ₃): 1.5-2.7 (m, 4H); 3.82 (d, J = 15.3 Hz, 1H); 3.9-4.25 (m, 1H); 5.01 (d, J = 15.3 Hz, 1H); 7.13 (s, 5H); 7.28 (d, J = 8.6 Hz, 2H); 7.68 (d, J = 8.6 Hz, 2H); 9.8-10.3 (m, 2H) [a]
10f	CH ₂ -Ph- <i>o</i> -Cl	CF ₃	1670-1685-1755 (C=O); 3180-3260 (N-H)	(CD ₃ OD): 1.95-2.6 (m, 4H); 3.9-4.25 (m, 1H); 4.07 (d, J = 15.0 Hz, 1H); 5.09 (d, J = 15.0 Hz, 1H); 7.33 (s, 4H)
10g	CH ₂ -Ph- <i>p</i> -CH ₃	CH ₂ -C ₄ H ₉ S	1630-1660-1710 (C=O); 3160-3210 (N-H)	(CDCl ₃ /DMSOd ₆ ; 70/30): 1.9-2.5 (m, 4H); 2.36 (s, 3H); 3.81 (d, J = 14.9 Hz, 1H); 3.84 (s, 2H); 3.9-4.25 (m, 1H); 5.05 (d, J = 14.9 Hz, 1H); 6.8-7.3 (m, 7H)

(a) These peaks disappear upon addition of deuterium oxide.

Scheme 6



disilylated compound **14** was more difficult to achieve, imidazole was added to the reaction medium; this catalyst yields *in situ* to *N*-trimethylsilylimidazole, a very potent silylating agent [23].

Although the yields in oxadiazoles are generally good, oxadiazole **8g** formed after refluxing for 36 hours could not be purified; oxadiazoles **8e** and **8f** have not been obtained under these one-pot conditions. We studied more precisely the reaction conditions and catalysts for compound **8e**:

-addition of a solvent, chlorobenzene, allowed the solubilization of the diacylhydrazine **10e** and thus made the silylation easier; by use of trimethylsilyl trifluoromethanesulfonate or tetrabutylammonium fluoride, oxadiazole **8e** was thus obtained in 33 and 69% yield, respectively.

-disilylated compound **14e** could be obtained by reflux of the diacylhydrazine **10e** with chlorotrimethylsilane in

triethylamine; it has been thermally cyclized (200-250°) under vacuum during a distillation attempt, affording the oxadiazole **8e** in 62% yield.

Refluxing the diacylhydrazine **10f** in HMDS in the presence of a catalytic amount of tetrabutylammonium fluoride only yielded the bis-silyl derivative **14f**. Cyclization of this isolated intermediate could be achieved by reflux with trifluoromethanesulfonic acid as a catalyst giving the oxadiazole **8f** in 70% yield.

In order to obtain oxadiazoles in one step from the corresponding pyroglutamic derivatives, we considered the action of a carboxylic acid on a pyroglutamic hydrazide in the presence of a silylating agent and a cyclization catalyst. This was tried with compound **10d** (HMDS/165°/several hours) but, although a mixture of silylated compounds was obtained, methanolysis only yielded the starting materials.

Table 5
Synthesis of Oxadiazoles **8**

Nb	R ₁	R ₂	M.p., °C	B.p.	Reaction Time (hours)	Purification Method [a]	Yield %	Formula	Analysis, %		
			(solvent)	(mm)					Calcd./Found	C	H
8a	CH ₃	CH ₃	80	145	30	A	81	C ₈ H ₁₁ N ₃ O ₂	53.03	6.12	23.19
8b	CH ₂ -Ph	CH ₃	CH ₂ Cl ₂ 86[b]	(0.25) 180	48	A	75		52.93	6.12	22.86
8c	CH ₂ -Ph	CH ₂ -O-Ph- <i>p</i> -Cl	CH ₃ OH 109	(0.15)	21	B	63	C ₂₀ H ₁₈ N ₃ O ₃ Cl	62.58	4.73	10.95
8d	CH ₂ -Ph	Ph-3,4,5-(OCH ₃) ₃	C ₂ H ₅ OH 127		3	C	83	C ₂₂ H ₂₃ N ₃ O ₅	62.28	4.50	10.98
8e	CH ₂ -Ph	Ph- <i>p</i> -Cl	C ₂ H ₅ OH 138		24	D	69	C ₁₉ H ₁₆ N ₃ O ₂ Cl	64.54	5.66	10.26
8f	CH ₂ -Ph- <i>o</i> -Cl	CF ₃	C ₂ H ₅ OH oil	150 (0.20)	3[c]	A	81[d]	C ₁₄ H ₁₁ N ₃ O ₂ F ₃ Cl	64.57	5.63	10.14
									64.50	4.56	11.88
									64.63	4.36	11.88
									48.64	3.21	12.15
									48.88	3.45	12.01

[a] A = Vacuum Distillation; B = Crystallization from Ethanol; C = Crystallization from Ethanol and Activated Charcoal Workup; D = Crystallization from Chlorobenzene. [b] Lit [18] 86°. [c] Catalyst: CF₃SO₃H. [d] From the corresponding Bis Trimethylsilyl Diacyl Hydrazide

Table 6
Spectral Properties of New Oxadiazoles **8**

Nb	R ₁	R ₂	IR (nujol) cm ⁻¹	¹ H NMR (CDCl ₃) ppm
8a	CH ₃	CH ₃	1585 (C=N); 1685 (C=O)	2.15-2.75 (m, 4H); 2.55 (s, 3H); 2.81 (s, 3H); 4.7-5.0 (m, 1H)
8c	CH ₂ -Ph	CH ₂ -O-Ph- <i>p</i> -Cl	1440-1450-1580 (C=C arom.); 1605 (C=N)	1.95-2.9 (m, 4H); 4.16 (d, J = 14.6 Hz, 1H); 4.69 (d, J = 14.6 Hz, 1H); 4.65-5.0 (m, 1H); 5.07 (s, 2H); 6.7-7.55 (m, 4H); 7.20 (s, 5H)
8d	CH ₂ -Ph	Ph-3,4,5-(OCH ₃) ₃	1125 (C-O); 1490- 1570 (C=C arom.); 1590 (C=N); 1665 (C=O)	2.2-2.5 (m, 4H); 3.93 (s, 9H); 4.17 (d, J = 14.8 Hz, 1H); 4.75-5.0 (m, 1H); 4.80 (d, J = 14.8 Hz); 7.13 (s, 2H); 7.18 (s, 5H)
8e	CH ₂ -Ph	Ph- <i>p</i> -Cl	1490-1565 (C=C arom.); 1590 (C=N); 1685 (C=O)	2.1-2.95 (m, 4H); 4.27 (d, J = 14.5 Hz, 1H); 4.7-5.05 (m, 1H); 4.71 (d, J = 14.5 Hz, 1H); 7.18 (s, 5H); 7.47 (d, J = 9 Hz, 2H); 7.83 (d, J = 9 Hz, 2H)
8f	CH ₂ -Ph- <i>o</i> -Cl	CF ₃	1475-1560 (C=C, arom.); 1585 (C=N); 1705 (C=O)	2.1-2.8 (m, 4H); 4.48 (d, J = 15.7 Hz, 1H); 4.88 (d, J = 15.7 Hz, 1H); 4.7-5.1 (m, 1H); 7.22 (s, 4H)

Physical properties of the new oxadiazoles **8** are reported in Tables 5 and 6.

Antifungal activities of the various products prepared was tested *in vitro*, against the following fungi: *Rhizoctonia solani*, *Botrytis cinerea*, *Phytophthora infestans*, *Fusarium oxysporum*, *Colletotrichum lindemuthianum*, *Phaeosphaeria nodorum*, *Cercospora herpotrichoides*, and *Ustilago zeae*.

(5-Oxo-2-pyrrolidinyl)-1,3,4-oxadiazoles show more antifungal activity than 2-(5-oxo-2-pyrrolidinyl)benzimidazoles, although it is still weak. The more potent compound we synthesized in these series is oxadiazole **8e**. Intermediate compounds (pyroglutamic esters, hydrazides and diacylhydrazines) were also screened and in general they have very weak properties.

Antitumor activity was also looked for in these com-

pounds, but unsuccessfully [24].

EXPERIMENTAL

Melting points are uncorrected. The ir spectra were recorded on a Perkin Elmer 700 spectrometer, the nmr spectra on a Hitachi Perkin Elmer R-600 at 60 MHz, using tetramethylsilane as an internal reference. Elemental analyses were performed by the Central Microanalytical Department of CNRS in Thiais, France.

Benzimidazoles **7a-g**.

All the benzimidazoles **7a-g** were prepared according to the same procedure for which a typical example is given below (see also the reaction time and yields in Table 1). Physical properties (mp, ir, nmr) and the elemental analysis are given in Tables 1 and 2.

2-[*N*-(4-Chlorobenzyl)-5-oxo-2-pyrrolidinyl]benzimidazole (7d).

A mixture of 2.4 g (9.26 mmol) of *N*-(4-chlorobenzyl)pyroglutamic acid (**9d**) and 1.0 g (9.26 mmol) of *o*-phenylenediamine was heated at 165° for 2.5 hours (the reaction medium became blue), and then at 220° for 40 minutes (the reaction medium became yellow). After cooling, the residue was dissolved in ethanol, and dichloromethane was added. The mixture was neutralized with diluted sodium hydroxide, washed with water, dried over sodium sulfate, worked up with activated charcoal and crystallized with ether (58% crude yield). The residue was recrystallized from a mixture water/ethanol for analysis.

Pyroglutamic Hydrazides 12a-e.

All the pyroglutamic hydrazides **12a-e** were prepared according to the same procedure for which a typical example is given below. Physical properties (mp, ir, nmr) and the elemental analysis of the new compounds are given in Tables 3 and 4.

[*N*-(4-Methylbenzyl)pyroglutamoyl]hydrazine (12d).

Hydrazine monohydrate (7.9 g, 155 mmol) was slowly added with cooling to a solution of 25.0 g (101 mmol) of methyl *N*-(4-methylbenzyl)pyroglutamate in 50 ml of methanol. The solution was refluxed for 3 hours and filtered. The filtrate was concentrated and filtered. The solids were combined (24.7 g, 98% yield) and used without further purification for the next step. A small amount of this product was recrystallized from ethanol for analysis.

Diacylhydrazines 10a,c-g.

Physical properties (mp, ir, nmr) and the elemental analysis of the new compounds are given in Tables 3 and 4.

(*N*₁-Acetyl-*N*₂-(*N*-methylpyroglutamoyl))hydrazine (10a).

N-Methylpyroglutamic hydrazide (**12a**) (40.0 g, 0.25 mole) was fractionally added with cooling to 100.0 ml (1.06 moles) of acetic anhydride. The reaction mixture was stirred at room temperature for 13 hours and filtered. The solid was washed with ether and then dried in the air for several days. Diacylhydrazine **10a** was thus obtained in 89% yield and used without further purification for the cyclization reaction. A small amount of this product was recrystallized from ethanol for analysis.

(*N*₁-(4-Chlorophenoxyacetyl)-*N*₂-(*N*-benzylpyroglutamoyl))hydrazine (10c).

A solution of 4-chlorophenoxyacetyl chloride (17.4 g, 85 mmol) in 40 ml of anhydrous dichloromethane was slowly added to 20.0 g (85 mmol) of *N*-benzylpyroglutamic hydrazide (**12b**) and 8.6 g (85 mmol) of triethylamine in solution in 100 ml of anhydrous dichloromethane. The reaction mixture was stirred for 15 hours. A small amount of solid was removed by filtration. Dichloromethane (100 ml) was added and the solution was washed with water, dried over sodium sulfate, concentrated, and precipitated with acetone. The resulting solid was filtered and washed with ether. Diacylhydrazine **10c** was thus obtained in 75% yield and used without further purification for the cyclization reaction. A small amount of this product was recrystallized from ethanol for analysis.

(*N*₁-(3,4,5-Trimethoxybenzoyl)-*N*₂-(*N*-benzylpyroglutamoyl))hydrazine (10d).

A solution of 3,4,5-trimethoxybenzoyl chloride (16.5 g, 71

mmol) and *N*-benzylpyroglutamic hydrazide (16.6 g, 71 mmol) (**12b**) in 90 ml of pyridine was refluxed for 3 hours and stirred at room temperature overnight. The pyridine was evaporated, the residue dissolved in dichloromethane and washed with diluted hydrochloric acid, with an aqueous solution of sodium bicarbonate and then with water until neutralization. The solution was dried over sodium sulfate, and then concentrated. The product was crystallized from acetone at 0° overnight. The resulting solid was filtered, washed with acetone and recrystallized from ethanol. Analytically pure diacylhydrazine **10d** was thus obtained in 46% yield.

(*N*₁-(4-Chlorobenzoyl)-*N*₂-(*N*-benzylpyroglutamoyl))hydrazine (10e).

A solution of 4-chlorobenzoyl chloride (13.8 g, 79 mmol) in 90 ml of anhydrous dichloromethane was slowly added at 0° to 18.0 g (77 mmol) of *N*-benzylpyroglutamic hydrazide (**12b**) and 7.8 g (132 mmol) of triethylamine in solution in 165 ml of anhydrous dichloromethane. The reaction mixture was stirred overnight. The resulting solid was filtered. After concentration of the filtrate a second fraction of crystalline compound was filtered. The combined solids were washed with carbonated water. The product was dissolved in THF, dried over sodium sulfate and crystallized from THF. Analytically pure monohydrated diacylhydrazine **10e** was thus obtained in 67% yield.

(*N*₁-(Trifluoroacetyl)-*N*₂-(*N*-(2-chlorobenzyl)pyroglutamoyl))hydrazine (10f).

A solution of trifluoroacetic anhydride (19.4 ml, 138 mmol) in 100 ml of anhydrous dichloromethane was slowly added to a solution of 35.0 g (131 mmol) of *N*-(2-chlorobenzyl)pyroglutamic hydrazide (**12c**) in 200 ml of anhydrous dichloromethane. The reaction mixture was stirred for 48 hours. The resulting solid was filtered, washed with ether, and dried under vacuum. Diacylhydrazine **10f** was thus obtained in 72% yield and used without further purification for the cyclization reaction. A small amount of this product was recrystallized from ethanol, and then from dichloromethane for analysis.

(*N*₁-(2-Thiopheneacetyl)-*N*₂-(*N*-(4-methylbenzyl)pyroglutamoyl))hydrazine (10g).

A solution of 2-thiopheneacetyl chloride (6.7 g, 42 mmol) in 50 ml of anhydrous dichloromethane was slowly added with cooling to 10.0 g (40 mmol) of *N*-(4-methylbenzyl)pyroglutamic hydrazide (**12d**) and 4.1 g (41 mmol) of triethylamine in solution in 125 ml of anhydrous dichloromethane. The reaction mixture was stirred for 17 hours. The resulting solid was filtered. After concentration of the filtrate and crystallization with ether, a second fraction of crystalline compound was filtered. The concentration, crystallization, and filtration steps were repeated twice. The combined solids were washed with an aqueous solution of sodium hydroxide. Traces of the starting hydrazide were removed by washing with THF. Diacylhydrazine **10g** was thus obtained in 77% yield and used without further purification for the cyclization reaction. A small amount of this product was treated with activated charcoal in ethanol, washed with ether and recrystallized twice from ethanol for analysis.

1,3,4-Oxadiazoles 8a-f.

The oxadiazoles **8a-d** were prepared according to the same

procedure for which a typical example is given below. For the syntheses of 2-(*N*-benzyl-5-oxo-2-pyrrolidinyl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazole (**8d**), 0.05 g of imidazole was added to the reaction medium. Physical properties (mp, ir, nmr) and the elemental analysis of the new compounds are given in Tables 5 and 6.

2-(*N*-Methyl-5-oxo-2-pyrrolidinyl)-5-methyl-1,3,4-oxadiazole (**8a**).

A mixture of 6.0 g (30 mmoles) of (*N*₁-acetyl-*N*₂-(*N*-methylpyroglutamoyl))hydrazine (**10a**), 7.8 g (48 mmoles) of hexamethyldisilazane (HMDS) and 0.05 g of tetrabutylammonium fluoride trihydrate was heated at 130° for 13 hours under nitrogen. The remaining HMDS and the obtained hexamethyldisiloxane were evaporated and the residue worked up as described in Table 5 and recrystallized in the suitable solvent (see Table 5).

2-(*N*-Benzyl-5-oxo-2-pyrrolidinyl)-5-(4-chlorophenyl)-1,3,4-oxadiazole (**8e**).

a) A solution of 4.0 g (10 mmoles) of (*N*₁-(4-chlorobenzoyl)-*N*₂-(*N*-benzylpyroglutamoyl))hydrazine (**10e**), 4.4 g (27 mmoles) of hexamethyldisilazane (HMDS), 0.05 g of tetrabutylammonium fluoride trihydrate and 0.05 g of imidazole in 10 ml of chlorobenzene was heated at 130° for 24 hours under nitrogen. The solid was filtered and washed with ether. By concentrations of the filtrate and filtrations, 3 new fractions were obtained. The total yield of oxadiazole **8e** was 69%. The product was recrystallized from ethanol.

b) Oxadiazole **8e** was obtained in 33% by the same procedure with trimethylsilyl trifluoromethanesulfonate (3 drops) instead of tetrabutylammonium fluoride trihydrate; 35% of the starting diacylhydrazine **10e** was also obtained during the crystallization.

c) A solution of 10.0 g (27 mmoles) of (*N*₁-(4-chlorobenzoyl)-*N*₂-(*N*-benzylpyroglutamoyl))hydrazine (**10e**) in 50 ml of triethylamine was refluxed. A solution of 14 ml (18 mmoles) of chlorotrimethylsilane in 20 ml of triethylamine was slowly added. The reaction medium was refluxed for 17 hours. The triethylamine hydrochloride was filtered under nitrogen and washed with anhydrous toluene. The solvents were evaporated and the residue, heated at 250° for a few minutes. By fractionated crystallization from ethanol, 5.9 g of oxadiazole **8e** (62%) and 1.1 g of diacylhydrazine **10e** (11%) were obtained.

Bis(trimethylsilyl)(*N*₁-trifluoroacetyl-*N*₂-(*N*-(2-chlorobenzyl)pyroglutamoyl))hydrazine (**14f**).

A solution of 25.0 g (68 mmoles) of (*N*₁-(trifluoroacetyl)-*N*₂-(*N*-(2-chlorobenzyl)pyroglutamoyl))hydrazine (**10f**) and 0.05 g of tetrabutylammonium fluoride trihydrate in 33.3 g (206 mmoles) of hexamethyldisilazane was refluxed under nitrogen for 36 hours. The reaction mixture was distilled under vacuum. Bisilylated compound **14f** was thus obtained in 85% yield (bp_{0.35} = 185°); ¹H-nmr (deuteriochloroform): δ (ppm) 0.20 (s, 9H), 0.29 (s, 9H), 1.95-2.8 (m, 4H), 4.10 (d, J = 15.6 Hz, 1H), 4.05-4.3 (m, 1H), 5.03 (d, d, J = 15.6 Hz, 1H), 7.23 (s, 4H).

2-(*N*-(2-Chlorobenzyl)-5-oxo-2-pyrrolidinyl)-5-trifluoromethyl-1,3,4-oxadiazole (**8f**).

A mixture of 6.0 g (12 mmoles) of bis(trimethylsilyl)(*N*₁-trifluoroacetyl-*N*₂-(*N*-(2-chlorobenzyl)pyroglutamoyl))hydrazine (**14f**) and 0.2 ml of trifluoromethanesulfonic acid was heated at 140° for 3 hours, the obtained hexamethyldisiloxane being removed by distillation as soon as it is formed. Oxadiazole **8f** was distilled under vacuum (bp_{0.20} = 150°) and thus obtained in 81% yield.

REFERENCES AND NOTES

- [1] Parts of this work have already been reported: P. Cauliez, B. Rigo, P. Halama and D. Couturier, 2èmes Journées Franco-Belges de Pharmacochimie, Bruxelles, Belgium, 1988; P. Cauliez, B. Rigo and D. Couturier, 12th International Congress of Heterocyclic Chemistry, Jerusalem, Israel, 1989.
- [2] G. Mazzone and F. Bonina, *Farmaco, Ed. Sci.*, **33**, 438 (1978); M. Vincent, J. Maillard and M. Bénard, *Bull. Soc. Chim. France*, 1580 (1962); C. Ainsworth, US Patent 2,702,803 (1955); *Chem. Abstr.*, **50**, 1088a (1956); Angelini Francesco Aziende Chimiche Riunite s.n.c., British Patent 1,161,801 (1969); *Chem. Abstr.*, **72**, 112937h (1969); Uniroyal, Inc., Canadian Patent 986,123 (1976); *Chem. Abstr.*, **85**, 33025v (1976); Philagro S.A., German Patent 2,808,842 (1978); *Chem. Abstr.*, **90**, 23060s (1979).
- [3] Farbenfabriken Bayer A.-G., German Patent 1,956,510 (1971); *Chem. Abstr.*, **75**, 36042c (1971).
- [4] P. Leroux, *La Défense des Végétaux*, **207**, 59 (1981).
- [5] K. Maekawa and J. Ohtani, *Agr. Biol. Chem.*, **40**, 791 (1976).
- [6] S. S. Kulakenko and N. A. Gracheva, *Khim. Geterosikl. Soedin.*, **7**, 773 (1971); *Chem. Abstr.*, **76**, 25007q (1972).
- [7] V. A. Sedavkina, N. A. Morozova, V. F. Chulkov and L. K. Kulikova, *Pharm. Chem. J.*, **16**, 44 (1982); G. V. Bessalova, V. A. Sedavkina, V. G. Kharchenko and L. K. Kulikova, *ibid.*, **15**, 38 (1981); V. A. Sedavkina, N. A. Morozova, A. A. Rechinskaya and L. K. Kulikova, *Khim. Farm. Zh.*, **8**, 21 (1974); *Chem. Abstr.*, **80**, 82870x (1974); A. A. Ponomarev and V. A. Sedavkina, *Chem. Heterocyclic Comp.*, 598 (1969).
- [8] B. Rigo, C. Lespagnol and M. Pauly, *J. Heterocyclic Chem.*, **23**, 183 (1986); Laboratoires Sérologiques S. A., European Patent 135,144 (1985); *Chem. Abstr.*, **103**, 123914d (1985).
- [9] N. Kolocouris and B. Rigo, *Chim. Chron., New Ser.*, **11**, 309 (1982); P. Cauliez, B. Rigo, D. Fasseur and D. Couturier, *J. Heterocyclic Chem.*, **28**, 1143 (1991).
- [10] B. Rigo, D. Fasseur, N. Cherepy and D. Couturier, *Tetrahedron Letters*, **30**, 7057 (1989).
- [11] W. O. Pool, H. J. Harwood and A. W. Ralston, *J. Am. Chem. Soc.*, **59**, 178 (1937).
- [12] G. Pellizari and A. H. Reale, *Acad. Lincei*, **8**, 327 (1899).
- [13] T. R. Vakula and V. R. Srinivasan, *Indian J. Chem.*, **11**, 732 (1973).
- [14] F. H. McMillan, F. Leonard, R. I. Meltzer and J. A. King, *J. Am. Pharm. Assoc. (Sci. Ed.)*, **42**, 457 (1953).
- [15] F. N. Hayes, B. S. Rogers and D. G. Ott, *J. Am. Chem. Soc.*, **77**, 1850 (1955); M. Robba, D. Maume and J. C. Lancelot, *Tetrahedron Letters*, **35**, 3239 (1973).
- [16] F. D. Popp, *J. Chem. Soc.*, 3505 (1964).
- [17] T. Mukaiyama and T. Hata, *Bull. Chem. Soc. Japan*, **34**, 99 (1961).
- [18] B. Rigo and D. Couturier, *J. Heterocyclic Chem.*, **23**, 253 (1986).
- [19] B. Rigo, D. Valligny, S. Taisne and D. Couturier, *Synth. Commun.*, **18**, 167 (1988).
- [20] B. Rigo, P. Cauliez, D. Fasseur and D. Couturier, *ibid.*, **16**, 1665 (1986); B. Rigo, P. Cauliez, D. Fasseur and D. Couturier, *ibid.*, **18**, 1247 (1988); B. Rigo, D. Fasseur, P. Cauliez and D. Couturier, *ibid.*, **19**, 2321 (1989).
- [21a] B. Rigo and D. Couturier, *J. Heterocyclic Chem.*, **22**, 287 (1985); [b] N. Kolocouris, Thesis, Lille (France) (1977); [c] R. B. Angier, C. W. Walker, B. L. Hutchings, J. H. Boothe, J. H. Mowat, J. Semb and Y. Subbarow, *J. Am. Chem. Soc.*, **72**, 74 (1950); [d] J. Bernstein, K. A. Losee, C. I. Smith and B. Rubin, *ibid.*, **81**, 4443 (1939); [e] M. Sy, C. Pilet, M. Maillet and M. Niel, *Chim. Ther.*, **4**, 231 (1966).
- [22] B. Rigo, J. de Quillacq, E. Fossaert and N. Kolocouris, *J. Heterocyclic Chem.*, **21**, 1393 (1984).
- [23] E. Colvin, Silicon in Organic Synthesis, Butterworth, London, 1971; W. P. Weber, Silicon Reagents for Organic Synthesis, Springer-Verlag, Berlin, 1983; I. Flemming, *Chem. Soc. Rev.*, **16**, 83 (1981).
- [24] Developmental Therapeutic Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland.